In yeast strains bearing the point mutation called GAL11P (for potentiator), certain GAL4 derivatives lacking any classical activating region work as strong activators. The P mutation confers upon GALl1, a component of the RNA polymerase II holoenzyme, the ability to interact with a portion of the dimerization region of GAL4. The region of GALl1 affected by the P mutation is evidently functionally inert in ordinary cells, suggesting that this mutation is of no functional significance beyond creating an artificial target for the GAL4 dimerization fragment. From these observations and further analyses of GALl 1, we propose that a single activator-holoenzyme contact can trigger gene activation simply by recruiting the latter to DNA.
Introduction
According to our current picture, gene activation requires interaction of DNA-bound activators with proteins binding near the transcription start site of a gene. A typical transcriptional activator bears distinguishable DNA-binding and activating regions (Ptashne, 1988) . In eukaryotes, activation of polymerase II genes requires, in addition to RNA polymerase, many transcription factors, and activating regions have been shown to contact one or another of these, including TATA-binding protein (TBP), TBPassociated factors (TAFs), TFIIB, and TFIIH (Roeder, 1991 ; Zawel and Reinberg, 1993; Conaway and Conaway, 1993; Hoey et al., 1993) . One strong activating region (that found on virion protein 16 [VP16]) has been reported to contact all of these four proteins (Stringer et al., 1990; Goodrich et al., 1993; Xiao et al., 1994) . These findings, taken with the results of a wide array of experiments performed in vitro, have led to the suggestion that transcriptional activation involves a multistep assembly process, various steps of which might be catalyzed by activators (Buratowski et al., 1989; Choy and Green, 1993) . It has been proposed, for example, that activating regions recruit one or more of these factors to DNA, or cause crucial conformational changes in target proteins that initiate the complex process of assembling the transcriptional 1Present address: Istituto Scientifico H. S. Raffaele, Dipartimento di Ricerca Biologica e Tecnologica, Via Olgettina 58,1-20132 Milan, Italy. apparatus, or do both Roberts and Green, 1994; Hori and Carey, 1994 ). An alternative and simpler scenario has been suggested by the finding that in yeast, RNA polymerase II and multiple transcription factors associate in the absence of DNA to form a so-called holoenzyme (Koleske and Young, 1994; Kim et al., 1994) . According to that scenario, recruitment of the holoenzyme would suffice for gene activation (Koleske and Young, 1994; Carey, 1994) .
The experiments reported here describe a specific instance of gene activation in yeast that is consistent with the latter picture. Our experiments identify a single protein, protein interaction that triggers gene activation. We show that a point mutation converts an apparently inert surface of a component of the holoenzyme into a new and evidently arbitrary interaction site for a peptide that is devoid of any classical activating function. A fusion protein bearing this latter peptide attached to a DNA-binding domain is a strong transcriptional activator that works only in cells bearing the new target. The simplest explanation for these results, when considered with further analyses of the novel target protein, is that interaction between a DNA-bound protein and a single component (perhaps any component) of the holoenzyme can recruit the latter to DNA and thereby activate gene transcription.
Our findings arose from our attempts to explain the properties of a yeast mutant in which certain weak derivatives of the transcriptional activator GAL4 work as strong activators (Himmelfarb et al., 1990) . The yeast mutant bears a single amino acid change in the protein GALl1 to form GAL11P (for potentiator). The mutation changes Asn to lie at position 342 of this 1081 amino acid protein (see legend to Figure 6 ). We show, using a combination of genetic and biochemical analyses, that the mutation in GALl 1P, which lies in a functionally inert part of the protein, promotes a novel interaction between GALl1 and a segment of the dimerization region (not the activating region) of GAL4. We confirm the finding that GALl1 is part of the holoenzyme, and we propose that the GALl 1P-GAL4 interaction recruits the holoenzyme and thereby triggers gene activation. A prediction of this model is that wild-type GALl 1 fused to a DNA-binding domain activates transcription by interacting with its partners in the holoenzyme, and we present experiments supporting this idea.
Results
Our experiments utilize a variety of protein fragments, some of which are analyzed as fusions. These include GAL4 derivatives that contain at least residues 1-93 and ranging up to residues 1-100, all of which contain DNAbinding and dimerization domains but no activating regions; GAL4(1-147), which also forms DNA-binding dimers and does not activate transcription in yeast; , which contains two activating regions but does not bind DNA (Ma and Ptashne, 1987; Reece and Ptashne, 1993 Figure 1 . The Effects of GALl1 and GALl 1P on Different Activators Three otherwise isogenic derivatives of strain FY250 (a gift of F. Winston) were constructed carrying a low copy plasmid containing either GALll, GAL11P, or no GALl1 allele. Each strain also bore a second low copy plasmid expressing the indicated transcriptional activator from the ACT1 promoter. Each strain was deleted for the chromosomal GAL4 and GALl1 genes, and the depicted reporter was integrated at the URA3 locus. The strain used to measure the activity of GCN4, which activates many amino acid biosynthetic genes, was also deleted for the chromosomal GCN4 gene. In this and the other figures of this paper, activity is given in units of I~-galactosidase activity per amount of protein in a whole-cell extract.
1), a close relative of GAL4 with DNA-binding and dimerization domains (but no activating region) in residues 29-123 (Marmorstein and Harrison, 1994) ; PUT3, another close relative of GAL4 with DNA-binding and dimerization (but no activating regions) in residues 31-100 (Reece and Ptashne, 1993) ; LexA, a 202 amino acid bacterial repressor, the first 87 amino acids of which contain the DNAbinding domain (Ruden et al., 1991) ; AH (for amphipathic helix), a synthetic 15 amino acid peptide that confers a weak activating function to a DNA-binding molecule; and SH (for scrambled helix), a related sequence that lacks the activating function (Giniger and Ptashne, 1987) .
GALl 1 GALl1 was originally identified as a protein required for efficient galactose utilization in yeast (Nogi and Fukasawa, 1980) . We and others showed that in cells deleted for GALl1, activation by GAL4 is reduced some 3-to 5-fold. This effect cannot be accounted for by decreased levels of the activator, because overexpression of GAL4 does not overcome the GALl 1 requirement for full activation (Himmelfarb et al., 1990; Suzuki et al., 1988; Long et al., 1991) . Figure 1 shows four activators, GAL4, GAL4(1-147)+AH, LexA(1-202)+AH, and GCN4, the latter two of which are unrelated to GAL4, that require GALl1 for full activity. Thus, contrary to our original surmise (Himmelfarb et al., 1990) , at least some activators lacking GAL4 sequences, as well as GAL4-derived activators, require GALl I for full activity. Consistent with this view is the fact that gall1 mutants have been isolated in screens involving transcription of genes unrelated to the GAL genes (Fassler and Winston, 1989; Vallier and Carlson, 1991 ; S. J. Kron and G. R. Fink, personal communication) . Sakurai et al. (1993) have reported that, in vitro, omission of GALl I decreases basal transcription (i.e., transcription seen in the absence of activators). These results, taken together, suggest that GALl1 is part of the transcriptional apparatus that is required for full activity at many yeast promoters. In experiments performed in vivo, we typically assay the function a ~, Sup.
GALl1: P w t --P w t -- of activator-stimulated promoters, and so the effect of GALl1 is detected as an effect on gene activation. We emphasize, however, that there is no evidence suggesting that GALl 1 is the target of any natural transcriptional acti-vating region, and that its effect is not restricted to genes or activators involved in galactose metabolism. Figure 2 shows that GALl1 is found exclusively, or nearly so, as part of the RNA polymerase II holoenzyme. This holoenzyme complex, as isolated by Koleske and Young (1994) , comprises at least 30 proteins, including RNA polymerase II, the general transcription factors TFIIB, TFIIF, and TFIIH, and at least four SRB (for suppressor of RNA polymerase B) proteins. Figure 2A shows that precipitation from a nuclear extract of Myc-tagged GALl 1 with a Myc antibody coprecipitates SRB4, a component of the holoenzyme. The precipitate also contains SRB5 (data not shown). The first panel of Figure 2B shows that the holoenzyme purified and characterized by Koleske and Young (their gift) contains GALl1. This experiment was performed by subjecting purified holoenzyme to SDSpolyacrylamide gel electrophoresis (SDS-PAGE) and then immunoblotting with antibodies raised against GALl1. Scanning densitometry analysis of the autoradiogram suggests that the amount of GALl 1 present in 1 I~g of holoenzyme (lane 1) is about 7-fold greater than the amount found in 200 I~g of a GALl 1 + nuclear extract (lane 4). Taken with the degree of purification of the holoenzyme used in this experiment (about 1000-fold from nuclear extracts), this result suggests that most or all of the GALl 1 in the nucleus is in the holoenzyme. This conclusion is supported by the results of an experiment in which the same filter probed for GALl 1 ( Figure 2B , first panel) was successively washed and reprobed for SRB4 (second panel) and then for RPB1, the largest subunit of yeast RNA polymerase II (third panel). Thompson and Young (1995) have deduced that SRB4 is found exclusively, or nearly so, in the holoenzyme, whereas a large fraction of RNA polymerase II is not. Lanes 1, 2, and 4 of the first and second panels indicate that in this experiment, the fraction of SRB4 that is recovered in the holoenzyme is indistinguishable from the fraction of GALl I so recovered. In contrast, the third panel reveals that, as expected, a much smaller fraction of RNA polymerase II is present in the holoenzyme. These results are also consistent with the finding of Kim et al. (1994) that GALl 1 is part of their so-called mediator complex that associates with RNA polymerase II.
GALl 1P
In contrast with the requirement for wild-type GALl1 for full activation by many activators, the mutant GALl 1P potentiates the activities of certain weak GAL4 derivatives only. Thus, for example, the activity of GAL4(1-147)+AH is some 10-to 100-fold higher in GALl 1P than in wild-type cells (see, for example, Figure 1 , line 2; Himmelfarb et al., 1990 , Table 1 ). As shown in line 1 of Figure 1 , native GAL4 is not potentiated when assayed on a reporter bearing consensus GAL4-binding sites. However, when binding of GAL4 is impaired by mutation either of the DNA site or of the protein, and activation thereby weakened, potentiation is observed (Himmelfarb et al., 1990 ; data not shown). Figure 1 also shows that two other activators lacking GAL4 sequences (LexA(1-202)+AH and GCN4) are unaffected by GALl 1P. Each of these activators works indistinguishably in GALl1 wild-type and GAL11P cells, and less well .B-gal ~ c.tivi1~. Figure 3. GAL4 Residues 58-97 Constitute an Activating Region in GALl 1P Cells (A) GAL4(58-97) fused to LexA activates in GAL11P cells. The indicated fusion proteins were expressed from the ACT1 promoter on a low copy plasmid. GALl1 proteins were expressed from the GALl1 promoter on low copy plasmids. The strain used in these experiments is JPY42 and is ga/4-and ga/11-. The integrated reporter template has two LexA-binding sites positioned 50 bp upstream of the GALl TATA box.
(B) GAL4 residue 97 is the carboxyl border of the novel activating region. Deletion derivatives of GAL4 were expressed from the ACT1 promoter on a low copy plasmid. GALl1 alleles were those described in (A). The strain used in these experiments is JPY16 and is gal4-and gall1-. The integrated reporter template has the UASG (an element that includes the GAL4-binding sites) at its native position upstream of the GALl TATA box.
(C) Mutations in GAL4(58-97) impair the novel activating region. LexA(1-202)+GAL4(50-147)+AH, bearing either no mutations or the indicated amino acid substitutions, was expressed from the ACT1 promoter on a low copy plasmid. GALl 1 alleles were those described in (A). The strain used in these experiments is JPY42.
in gall1-cells. In a previous publication, we reported that the yeast activator PPR1 (which bears a DNA-binding domain similar to that of GAL4) responded to GALl 1P (Himrnelfarb et al., 1990) . We believe this result to have been incorrect; we now find that PPR 1 and the weakly activating derivative PPR1(1-123)+AH have the same activity in GALl1 wild-type and GALllP cells (data not shown).
In the following paragraphs, we first show that part of
Tagged ( GALl1 and GALl 1 derivatives were expressed from the GALl1 promoter on a low copy plasmid. GAL4(1-147)+AH was expressed from the ACT1 promoter on a low copy plasmid. The strain used in this experiment (YT6) is gal4-and gall1-. The indicated reporter gene, which has the UAS~ at its native position upstream of the GALl TATA box, was integrated at the URA3 locus.
the dimerization domain of GAL4 works as an activating region in GAL 11P cells; second, demonstrate in vitro that this fragment of GAL4 interacts specifically with GALl 1 P; third, analyze changes in GALl 1 that confer the GALl 1P phenotype; and fourth, argue that the region of GALl1 that bears the site of the GAL11P mutation is ordinarily functionally inert.
GAL4(58-gz) Activates Transcription in GAL11P Cells
As shown in Figure 3A (line 4), Each of these proteins is expressed and, as assayed in cell extracts, binds DNA with similar efficiency (data not shown). These results define the carboxyl border of the novel activating region to be residue 97. Figure 3A shows that the same carboxyl border is observed with GAL4 peptides fused to LexA and assayed on a gene bearing LexA sites in a GAL11P cell. The amino border of the activating element evidently lies near residue 58, because deletion of four amino-terminal residues to form, for example, Lex-A+GAL4(62-97), inactivates each of the derivatives in Figure 3A (data not shown). The conclusion that GAL4 residues 58-97 carry the GALl 1 P recognition site is further supported by the following observation. We mutagenized a LexA-GAL4 derivative bearing the activating region AH and found two mutants that activated normally or nearly so in wild-type cells but that, compared with the parent, were impaired for activation in GAL11P cells. These mutations substituted Gly for Arg at position 63 and Arg for Gin at position 66; their effects are shown in Figure 3C .
Residues 58-97 comprise part of the dimerization r~e -gion of GAL4. The crystal structure ofGAL4(1-65) reveals a coiled coil that originates at residue 50 and continues through residue 64 (Marmorstein et al., 1992) . We do not know whether this coiled coil continues uninterrupted through residue 97. In Vitro, Peptides Containing GAL4 Residues 58-97 Interact with GALllP but Not with GALl1 To study the GAL4-GAL11P interaction in vitro, we purified a shortened (so-called mini) form of GALl 1 (comprising residues 261-351 plus 799-1081) with or without the P mutation at residue 342. Each of these derivatives also contains a run of 6 His residues and a 10 amino acid Myc epitope at its amino terminus. Mini-GALl 1 works about as well as does full-length GALt 1 in helping GAL4 to activate transcription ( Figure 4 , lines 1 and 4), and mini-GALl1P works about as well as full-length GAL11P in helping GAL4(1-147)+AH to activate (Figure 4 , lines 3 and 5). The binding experiment was performed by attaching either of these tagged GALl1 or GALl 1P proteins to a newly designed chip displaying nickel atoms (G. S., C. B., A. B., J. Strominger, and G. Whitesides, unpublished data) and testing for their interaction with eight purified proteins in a BIAcore instrument (Chaiken et al., 1992) . The following five proteins, each of which bears GAL4 residues 58-97, bound to mini-GAL11P: GAL4(1-147)+AH, GAL4(1-147)+SH, PUT3(31-79)+GAL4(58-100), GAL4 (1-100), and GAL4(1-147); data for the first three of these proteins are shown in Figures 5A , 5B, and 5C. In contrast, the following proteins, each of which lacks part or all of GAL4(58-97), failed to bind to GALlt P: GAL4(1-94), PPR1(29-123), and PUT3(1-100)+AH (Figures 5A and 5B). Mini-GALl1 wild type did not bind significantly to PUT3(1-100)+AH, GAL4(1-147)+AH, or GAL4(1-147), as shown in Figure 5D . The two forms of mini-GALl1 interacted equally well with Myc antibodies, and a mixture containing equal amounts of mini-GALl 1 wild type and mini-GAL11P bound various proteins bearing GAL4(58-97) (data not shown).
Substitution of Various Hydrophobic Residues for Asn at Position 342 Creates the GAL llP Phenotype
As previously noted, the original GALl 1P mutant bore an lie residue at position 342 (Himmelfarb et al., 1990) . Randomization of codon 342 revealed that substitution with other hydrophobic residues yields the GALl 1 P phenotype to different extents. Thus, as shown in Figure 6 , Leu or Val at position 342 mimics the effect of lie at that position (Val conferring in fact a stronger effect when assayed with LexA+GAL4(58-97), a molecule that lacks a classical activating region), and Met or Thr confers a somewhat weaker effect.
The effect of GALl 1P is not readily mimicked by mutation elsewhere. We reached this conclusion by repeating with some modifications the original screen of Himmelfarb et ai. (1990) , using an activator, GAL4(1-238), that bears only one of the two principal activating regions of GAL4 (Ma and Ptashne, 1987) . We found that of 15 mutations unlinked to the activator gone, all were mutated to lie at residue 342 of GALl I (Reinagel, 1994 (1-50o) 119o As shown in Figure 6 , GALl1 mutants bearing Gly, Asp, or Trp at position 342 behave indistinguishably from wildtype GALl1. The figure also shows that deletion o f residues 337-347 has no effect on the activity of wild-type GALl 1. These results support the idea that the GALl 1P mutation has introduced an entirely novel function to the protein, making it the fortuitous target of a peptide that otherwise has no activating function.
LexA-GAL11
GALl 1 fused to LexA and bound to LexA sites is an extraordinarily powerful activator of transcription in yeast (Himmelfarb et al., 1990) . When compared using reporters differing only in the nature of activator-binding sites positioned about 100 bp upstream of the TATA box, LexA-GAL11 and LexA-GAL11P activated indistinguishably and at least as strongly as did GAL4, itself a very strong activator in yeast (Himmelfarb et al., 1990 ; data not shown). More recent experiments in which the activators were positioned some 1200 bp upstream of the TATA box revealed that LexAGALl 1 activated some 10-to 20-fold more efficiently than LexA-GAL4 (L. Gaudreau, V. Goldburt, and M. P., unpublished data). The facts that GALl1 is part of the holoenzyme and that GAL11P is the target of GAL4(58-97) suggest that LexA-GAL11 activates transcription by interacting with its ordinary partners in the holoenzyme. According to this idea, LexA-GAL11 does not bear a classical activating region; rather, it forms part of the holoenzyme and, by binding to DNA through its LexA moiety, recruits the holoenzyme to the template. The notion that LexAGALl1 forms part of the holoenzyme is highly plausible in view of the finding that LexA-GAL11 functions as efficiently as does wild-type GALl1 in helping (for example) GAL4 to activate transcription (see Figure 7C , lines 1 and 7; Himmelfarb et al., 1990) . We infer that activation by as proteins present in the supernatant (Sup.), were analyzed by immunoblotting with antibodies directed against SRB4, a component of the holoenzyme.
(C) The carboxyl region of GALl 1 is necessary and sufficient for GALl 1 activity. Derivatives of GALl1 were expressed from the GALl1 promoter on a low copy vector. The strain, JPY14, is isogenic to JPY17, except that it is GAL4 ÷, and the integrated reporter contains a UASa at its natural p~osition in the GALl promoter.
(D) Overexpression of GALl1 squelches activation by LexA-GAL11 but not activation by LexA-GAL4. The activities of LexA-GAL11 and LexA-GAL4 were determined in strain JPY27, which is gal4-. The activators were expressed from the ADH1 promoter on a low copy vector. The reporter gene shown was integrated at the URA3 locus. GALl1 was overexpressed by introducing a high copy plasmid expressing GALl1 from its own promoter.
DNA-bound LexA-GAL11 is similar to that effected by the interaction of DNA-bound GAL4(1-97) with GAL11P, the salient difference being that in the case of LexA-GAL11 (or LexA-GAL11P), the relevant surface of GALl I is tethered covalently to the LexA DNA-binding domain. The following three lines of argument further support this view. First, the activating region of GALl 1 interacts with components of the holoenzyme. Figure 7A shows that the activating region on GALl1 is contained primarily within its carboxy1282 residues. Thus, LexA+GAL11(799-1081) activates nearly as strongly as does LexA-GAL11 (compare lines 2 and 5 of Figure 7A ), whereas derivatives lacking this region activate much less efficiently ( Figure 7A , lines 3 and 4). Figure 7B shows that two GALl1 derivatives containing this carboxyl region coimmunoprecipitate with SRB4, a component of the holoenzyme, but that two GALl 1 derivatives lacking this carboxyl region do not. All four GALl 1 derivatives were expressed at similar levels, as determined by Western blot (data not shown).
Second, the activating region of LexA-GAL11 also provides a significant portion of the ordinary activator-helping function of GALl 1. Thus, as shown in Figure 7C , the carboxyl 282 residues of GALl 1 that are required for strong activation by LexA-GAL11, as determined in the experiment summarized in Figure 7A , are also required for the normal activity of GALl 1, as determined in the experiment summarized in Figure 7C , lines 1,2, and 3. Moreover, this carboxyl fragment of GALl1, both on its own and as a LexA fusion, provides about 60% of the helping effect of GALl 1 ( Figure 7C , lines 6 and 8; data not shown), presumably because it plays its ordinary role in the holoenzyme relatively efficiently.
Third, GALl 1 squelches activation by LexA-GAL11 but not that elicited by LexA-GAL4. The experiment shown in Figure 7D argues that the target contacted by the activating region on LexA-GAL11 differs from the site(s) contacted by a classical activating region, a result consistent with the idea that LexA-GAL11 contacts its bona fide partners in the holoenzyme when working as an activator. Thus, overexpression of GALl1 decreases (squelches) (Gill and Ptashne, 1988; Ptashne, 1988) activation by LexA-GAL11 but not by LexA-GAL4, an effect that is most simply understood as a consequence of saturation of the GALl 1 site in the complex with the overexpressed GALl 1. Such a saturation would prevent further interaction of DNA-bound LexA-GAL11 with its partners but would have no effect on the interaction of DNA-bound LexA-GAL4 with its target, whatever that might be.
Discussion
Our principal conclusions are represented in Figure 8 . Substitution with any of several hydrophobic residues at position 342 of GALl 1, a component of the RNA polymerase II holoenzyme, creates a novel site for interaction with a portion of GAL4. This region of GAL4 (included in residues 58-97) is part of its dimerization domain, and, whether as part of GAL4 or when fused to LexA as shown in Figure 8A , it has no activating function in wild-type cells.
In the presence of GALl 1P, however, the residues work as a powerful activating region, presumably by recruiting the holoenzyme to DNA ( Figure 8B ). As predicted by this model, and as shown in Figure 8C , GALl1 itself, when fused to a DNA-binding domain, works as a strong activator. These pictures should be considered along with the following considerations.
The simplest explanation for our results is that the gene activation we describe is effected by recruitment of the holoenzyme to DNA. A contrasting idea would be that interaction between GAL4(58-97) and GALl 1P introduces (for example) some conformational effect (e.g., that proposed to be the result of VP16-TFIIB interaction [Roberts and Green, 1994] ) or some enzymological modification that would be required to trigger gene activation. The recruitment idea is strongly suggested by our findings that Transcription factors TFIID and TFIIE, which are not part of the holoenzyme described by Koleske and Young (1994) , are not shown. (B) GAL4(58-97) works as an activating region in GAL11P cells because it specifically interacts with GALl 1P and thereby recruits the RNA polymerase II holoenzyme complex to the promoter. (C) A sequence-specific DNA-binding module fused to GALll(or to GALl 1 P) recruits the holoenzyme to the promoter and activates transcription.
the site on GALl 1 that mutates to GALl 1P lies in a functionally inert part of the protein. To our knowledge, there is no special significance to the fact that GALl 1 contains the mutation that creates a new target for an otherwise inactive activating region, other than that GALl1 is part of the holoenzyme. The recruitment model is further supported by the fact that tethering GALl 1 to DNA by fusion to a DNA-binding domain induces strong activation, and that the part of GALl 1 that works as an activating region in this scenario contacts other components of the holoenzyme. The results presented in this paper more broadly raise the possibility that natural activators also work by recruitment as well (see below). Our results suggest that interaction between a DNAbound protein and a single component of the holoenzyme is sufficient to trigger gene activation, at least at the following four yeast promoters: GALl, CYC1 (not shown), GAL80 (not shown), and HIS3 (not shown). It is hard for us to imagine, for example, that GAL4 residues 58-97 contact various components of the transcriptional machinery but work as an activating region only in GAL11P cells. If our line of reasoning is correct, strong activation does not, for example, require direct interaction of the activating region with machinery that helps remove nucleosomes. If such a machinery, e.g., the SNF/SWl complex (Kwon et al., 1994; C6te et al., 1994) , is required under our conditions, it might work constitutively to allow the transcriptional components to compete for access to DNA, or it might be brought to the DNA by interaction with some component of the transcriptional machinery.
The model of Figure 8 omits at least one important component of the transcriptional machinery, TFIID. We suspect that TFIID is indeed required for activation by GAL4(58-97) in GAL11P cells, and by LexA-GAL11, because in both instances, mutation of the TFIID-binding site (TATA) greatly decreased activation (data not shown). Recent experiments suggest that TFIID is not part of the holoenzyme, although an earlier report suggested it might be (Koleske and Young, 1994; Thompson et al., 1993) . We imagine that required components that are not part of the holoenzyme bind to DNA prior to recruitment of the holoenzyme or bind cooperatively with the latter when it is recruited in our experiments. For example, others have argued that TFIID is bound at the CYC1 promoter prior to activation , but that TFIID binds concomitantly with activation at the GALl and HIS3 promoters (Selleck and Majors, 1987; Klein and Struhl, 1994) ; as mentioned above, we observe activation by contact with the holoenzyme at all of these promoters. Two forms of the holoenzyme lacking TBP have been described. Koleske and Young (1994) isolated a complex that includes, in addition to RNA polymerase and several SRB proteins, the transcription factors TFIIB, TFIIH, and TFIIF; our experiments show that GALl 1 is also part of this complex. Kim et al. (1994) described a complex of RNA polymerase II with a so-called mediator component that includes GALl1 but does not include TFIIB and TFIIH, and they showed that, in vitro, optimal transcription requires this mediator.
As mentioned in the Introduction, several different classical activator-transcription factor interactions have been described. To explain this plethora of interactions, Koleske and Young (1994) and Carey (1994) have proposed that activators can recruit the holoenzyme to DNA and thereby activate transcription by contacting one or another of several potential sites on the surface of the holoenzyme. Our results are consistent with that idea. We might further extend the idea by noting that two of the activating region targets listed in the Introduction are part of the TFIID complex (TBP and TAFs), and two are part of the holoenzyme as described by Koleske and Young (1994) (TFIIB and TFIIH) . If the holoenzyme binds cooperatively to DNA with other transcriptional components (e.g., TFIID), then activation might be triggered by interaction of an activating region with any of those components. It is conceivable that promoters differ in their affinities for different components, such that activator contact with one or another complex (e.g., TFIID or the holoenzyme), or both, is required for gene activation in any given case; activating regions that touch multiple components would be expected to work at many promoters. This general line of reasoning suggests that the many different activator-target interactions reported could each be biologically relevant.
The idea that activators can interact with different surfaces of the holoenzyme (or of TFIID) parallels our understanding of gene activation in Escherichia coll. There the bacterial polymerase, a multimer of subunits (~, 13, 13', and (~2, is isolated as the holoenzyme under one set of conditions and as core enzyme (lacking o) under another (Burgess et al., 1969) , and both (~ and the core have been identified as targets of activators: X repressor (working as an activator) is believed to contact a, and catabolite gene activator protein (CAP) contacts ~ . Moreover, recent experiments suggest that there may be several sites on (~, contact with any one of which suffices to recruit polymerase to DNA and activate transcription (Ishihawa, 1993) . Joung et al. (1994) have shown that ;~ repressor and CAP, bound to adjacent sites on DNA near a promoter, activate that promoter synergistically, evidently because two different surfaces of the polymerase holoenzyme are contacted by the two activators. It has been suggested that synergistic activation in eukaryotes requires interaction of activating regions with two or more targets (Carey et al., 1990) .
We know from examples in prokaryotes (e.g., activation of transcription by ;L repressor) that very weak proteinprotein interactions (in this case between X repressor and E. coil RNA polymerase) can trigger gene activation (Ptashne, 1992) . These weak interactions nevertheless have significant effects when the interacting components are binding cooperatively to DNA. The interaction we measure between GAL11P and GAL4(1-100) has a Kd of roughly 10 -7 M, as calculated from BIAcore data (Y. Wu, A. B., and M. P., unpublished data). Our experiments indicate that interactions of this order of affinity suffice for strong gene activation in yeast, and they suggest that bona fide activating regions might interact with their targets with similar affinities.
Experimental Procedures

Genetic Methods
Cells were grown and assayed for ~-galactosidase activity as described by Rose et al. (1990) . In all the figures of this paper, the numbers listed are the averages of three or more independent experiments; the standard error for cultures assayed in triplicate was less than 20%. Plasmids expressing deletion derivatives and fusion proteins were constructed by use of convenient restriction sites or by the polymerase chain reaction (PCR) using Pfu polymerase (Stratagene). Details of plasmid and strain construction are available upon request. Mutagenesis of a portion of the GAL4 dimerization domain for the experiment shown in Figure 3C was performed by chemical saturation mutagenesis as described by Myers et al. (1985) .
Yeast Extracts and Immunoassays
Whole-cell extacts were prepared according to the protocol of Woontner et al. (1991) , and nuclear extracts were prepared as described by Lue and Kornberg (1987) . Immunoprecipitation and Western blot assays were performed as described by Harlow and Lane (1988) .
Protein Purification
Mini-GALl 1 (261-351)+(799-1081 ), with or without the P mutation at residue 342, was tagged with six His residues and a Myc epitope (EQKLISEEDL) at its amino terminus and expressed in the yeast strain JELl (MATa leu2 trpl ura3-52 prb1-1122 pep4-3 •His3::pGALIO-GAL4, a gift of J. Lindsley) from the inducible GALl promoter on a high copy plasmid (LEU2 2~). Yeast cells carrying the mini-GALl1 expression plasmid were grown to saturation in 300 ml of selective medium containing 2% (w/v) glucose. This culture was used to inoculate 6 liters of selective medium containing 5% (w/v) glycerol. Cells were allowed to grow for 12-14 hr prior to the addition of galactose to a final concentration of 2% (w/v). After an 8 hr incubation, cells were collected by centfifugation and washed once in cold water. Whole-cell extracts were prepared as described by Woontner et al. (1991) and loaded on a 5 ml nickel-agarose column (Qiagen). After two rounds of extensive washing with, first, 10 mM imidazole in loading buffer (0.2 M Tris [pH 7.9], 0.39 M (NH4)~SO4, 10 mM MgSO4, 20% glycerol, 1.4 mM 2-mercaptoethanol, 0.1% Tween 20, and the following protease inhibitors: 1 mM phenylmethylsulfonyl fluoride, 0.2 mM benzamidine hydrochloride, 10 mM bestatin, 2 mM leupeptin, 2 mM pepstatin) and, second, 1 M urea in buffer NiD (20 mM Tris [pH 7.9], 100 mM KCI, 20% glycerol, 1.4 mM 2-mercaptoethanol, and the same protease inhibitors as in the loading buffer), tagged mini-GALl 1 proteins were eluted with a gradient of imidazole (10 mM-250 mM) in buffer NiD. All operations were performed at 4°C and monitored by an ultraviolet detector (Gilson). Fractions containing mini-GALl1 were pooled and extensively dialysed against buffer NiD. GAL4 derivatives and other DNA-binding proteins assayed in this study were expressed in bacteria and purified as described by Reece and Ptashne (1993) .
Protein Binding Assays
Surface plasmon resonance measurements were performed in a BIAcore instrument from Pharmacia Biosensor AB. BIAcore sensor chips (Pharmacia) were modified to bind His-tagged proteins by adsorbing a mixed monolayer of thiols presenting NF + bound to a nitrilotriacetic acid derivative on the gold surface. A description of the sensor chip preparation will appear elsewhere (G. S., C. B., A. B., J. Strominger, and G. Whitesides, unpublished data). The procedure involves a 5 ~_1/ min continuous flow of buffer (HEPES-buffered saline: 10 mM HEPES [pH 7.4], 150 mM NaCI) over the chip surface interrupted by 7 rain protein injections. All experiments were performed at room temperature, and His-tagged proteins stably bound to the chip surface without further modification.
